|
Case HBS Case Collection November 2017 BeiGene |
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window of opportunity to develop drug candidates toward known targets with known mechanisms of actions that would allow it to become first-in-class in China. But how well would the company's strategy hold up to the 2017 regulatory reforms?
Keywords: biotechnology; Pharmaceutical Company; pharmaceutical industry; Pharmaceuticals; China; regulatory environment; Business Strategy; Business Startups; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; China;
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
